Dr. Alan C. Moses served for nearly five years as the Chief Medical Officer and Senior Vice President of the Joslin Diabetes Center, specifically responsible for the operation of the Joslin Clinic. In 2004, Dr. Moses joined Novo Nordisk, Inc and retired in 2018 in the role of Global Chief Medical Officer. He was deeply involved in the development and approval of multiple insulin molecules and in the GLP-1 receptor agonists, liraglutide and semaglutide. During his academic career at Harvard Medical School, Dr. Moses was active in basic research, clinical research, clinical research administration, and training and achieved the rank of Professor of Medicine. He has written over 100 papers and articles on the treatment of diabetes, is an Editor of the Fourteenth edition of Joslin’s Diabetes Mellitus and has been recognized both locally and nationally for clinical care in diabetes and for his research in diabetes and growth factors. He currently serves of the Board of Directors of two nonprofit diabetes organizations: The diaTribe Foundation and the Joslin Diabetes Center.  He also serves as a member of the Board of Directors of BiomX and Chemomab, two clinical phase biotechnology companies. Dr. Moses serves as a consultant for several biotechnology and diabetes healthcare delivery companies.  He received a BS from Duke University and an MD from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, MO, the National Institutes of Health in Bethesda, MD, and Tufts-New England Medical Center in Boston. Dr Moses is board certified by the American Board of Internal Medicine and has subspecialty certification in Endocrinology and Metabolism.